ProCE Banner Activity

MM31: Treatment Update in Covid-19

Multimedia
In this presentation, Arthur Kim, MD, reviews recent EUAs for baricitinib, bamlanivimab, and casirivimab/imdevimab, as well as NIH guideline recommendations for ivermectin.

Released: January 25, 2021

Expiration: January 24, 2022

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Educational grant provided by

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he served as a site PI for an NIH-funded trial of casirivimab/imdevimab.